X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SANOFI INDIA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SANOFI INDIA DR. REDDYS LAB/
SANOFI INDIA
 
P/E (TTM) x 28.8 30.2 95.4% View Chart
P/BV x 3.0 5.3 55.7% View Chart
Dividend Yield % 1.0 1.7 56.4%  

Financials

 DR. REDDYS LAB   SANOFI INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
SANOFI INDIA
Dec-16
DR. REDDYS LAB/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs4,3834,560 96.1%   
Low Rs2,7504,400 62.5%   
Sales per share (Unadj.) Rs920.11,028.5 89.5%  
Earnings per share (Unadj.) Rs126.1129.0 97.8%  
Cash flow per share (Unadj.) Rs183.0186.0 98.4%  
Dividends per share (Unadj.) Rs20.0068.00 29.4%  
Dividend yield (eoy) %0.61.5 36.9%  
Book value per share (Unadj.) Rs685.8753.6 91.0%  
Shares outstanding (eoy) m170.6123.03 740.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.94.4 89.0%   
Avg P/E ratio x28.334.7 81.4%  
P/CF ratio (eoy) x19.524.1 80.9%  
Price / Book Value ratio x5.25.9 87.5%  
Dividend payout %15.952.7 30.1%   
Avg Mkt Cap Rs m608,481103,174 589.8%   
No. of employees `00021.73.6 598.1%   
Total wages/salary Rs m31,8743,592 887.4%   
Avg. sales/employee Rs Th7,244.46,537.7 110.8%   
Avg. wages/employee Rs Th1,470.9991.4 148.4%   
Avg. net profit/employee Rs Th992.8819.8 121.1%   
INCOME DATA
Net Sales Rs m156,97823,686 662.7%  
Other income Rs m2,693708 380.4%   
Total revenues Rs m159,67124,394 654.6%   
Gross profit Rs m34,5875,281 654.9%  
Depreciation Rs m9,7051,313 739.1%   
Interest Rs m82415 5,493.3%   
Profit before tax Rs m26,7514,661 573.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,2371,691 309.7%   
Profit after tax Rs m21,5142,970 724.4%  
Gross profit margin %22.022.3 98.8%  
Effective tax rate %19.636.3 54.0%   
Net profit margin %13.712.5 109.3%  
BALANCE SHEET DATA
Current assets Rs m118,20115,673 754.2%   
Current liabilities Rs m68,3686,678 1,023.8%   
Net working cap to sales %31.738.0 83.6%  
Current ratio x1.72.3 73.7%  
Inventory Days Days6076 78.9%  
Debtors Days Days9722 434.2%  
Net fixed assets Rs m72,2658,098 892.4%   
Share capital Rs m853230 370.4%   
"Free" reserves Rs m111,54817,088 652.8%   
Net worth Rs m117,00917,356 674.2%   
Long term debt Rs m10,6900-   
Total assets Rs m200,10425,400 787.8%  
Interest coverage x33.5311.7 10.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.9 84.1%   
Return on assets %11.211.8 95.0%  
Return on equity %18.417.1 107.4%  
Return on capital %21.626.9 80.1%  
Exports to sales %46.324.5 188.9%   
Imports to sales %9.028.0 32.0%   
Exports (fob) Rs m72,6185,801 1,251.8%   
Imports (cif) Rs m14,0506,627 212.0%   
Fx inflow Rs m75,4057,145 1,055.4%   
Fx outflow Rs m27,1156,846 396.1%   
Net fx Rs m48,290299 16,150.5%   
CASH FLOW
From Operations Rs m40,4763,226 1,254.7%  
From Investments Rs m-19,421-1,555 1,248.9%  
From Financial Activity Rs m-17,009-1,818 935.6%  
Net Cashflow Rs m4,046-147 -2,752.4%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.4 14.4 37.5%  
FIIs % 35.3 14.6 241.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 15,184 499.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Lupin up 4%(01:30 pm)

After opening the day flat, share markets in India remained rangebound and are presently trading marginally above the dotted line.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 24, 2017 02:52 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS